Orion Office REIT Inc vs Dr. Reddy's Laboratories Ltd Common Stock — how do they compare? Orion Office REIT Inc trades at $2.11 (market cap $119.79M), while Dr. Reddy's Laboratories Ltd Common Stock trades at $12.75 (market cap $10.61B). The key difference: Dr. Reddy's Laboratories Ltd Common Stock is far larger — about 88.6× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays the higher dividend (3.81%). Which is the better fit depends on your goals — on Pluang, investors hold Orion Office REIT Inc for 34 Days and Dr. Reddy's Laboratories Ltd Common Stock for 0 Days on average.
| ONL | RDY | |
|---|---|---|
Market Cap | $119.79M | $10.61B |
Volume | 347,277 | 3,738,869 |
Sector | Real Estate | Health |
52-Week High | $3.00 | $15.38 |
52-Week Low | $1.93 | $11.38 |
Typical Hold Time | 34 Days | 0 Days |
Enterprise Value | $536.73M | $10.51B |
Dividend Yield | 3.81% | 0.65% |
Signals from Pluang's Aura AI — not financial advice
ONL trades at $2.10, down 2.33% on the day, with a bearish technical signal despite oscillators showing some bullish momentum. The company reported Q2 2026 EPS of $0.42, beating expectations, but maintains negative net income margins and declining revenue trends from $208M in 2022 to $148M in 2025. Analyst consensus is split evenly between Buy and Hold ratings, with no Sell recommendations.
The outlook remains challenging with persistent net losses and high debt levels, though the deep discount to book value (P/B 0.19) offers potential upside if operational improvements materialize. Key risks include ongoing revenue contraction, negative profitability, and significant leverage exposure in the office REIT sector.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →Dr. Reddy's Laboratories Ltd. develops and manufactures generic medicines, active pharmaceutical ingredients (APIs), biosimilars, and over-the-counter (OTC) products, headquartered in Hyderabad, India, with therapeutic focus areas spanning gastrointestinal, cardiovascular, oncology, and dermatology.
Read more on RDY →